中文Vientiane, Laos - August 22, 2023 - Big Bear Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative treatments for cancer, announced today that seven products has been approved by the Lao Ministry of Health.
Approved drugs are:
Ixazomib: sold under the brand name ISADX. Ixazomib is an oral, highly selective proteasome inhibitor. It was first approved for marketing in the United States on November 20, 2015. Is an oral drug for multiple myeloma. Clinical research data proves that ixazomib combined with lenalidomide and dexamethasone (IRd) can significantly shorten the onset of action and extend the patient's survival by up to 10 months.
Lenalidomide: Sold under the brand name LENADX. Lenalidomide was approved by the US FDA in December 2005. As a new generation of immunomodulator, it has immunomodulatory, anti-angiogenesis and anti-tumor properties. In addition to being used in multiple myeloma clinically, it is also used in the treatment of lymphoma, myelodysplastic syndrome, acute myeloid leukemia and other diseases .
Mitotane: Sold under the brand name MITODX. Mitotane was approved by the Food and Drug Administration (FDA) in 1970 for the treatment of adrenocortical carcinoma. It was then approved for sale in Canada in 1978. Mitotane is currently the only drug approved for adrenocortical carcinoma.
Tofacitinib: sold under the brand name TOFADX. Tofacitinib is a Janus kinase inhibitor that can block Janus kinase and related signal transduction and transcription activator signal transduction pathways, reduce the production and release of various cytokines, and has the potential to treat a variety of rheumatic diseases. , which has the advantages of rapid onset of action, reduced dependence on glucocorticoids and related adverse events.
Tucatinib: sold under the brand name TUKADX. It will be approved by the US Food and Drug Administration (FDA) for marketing in 2020. Tucatinib is highly selective for HER2 and can inhibit the growth of HER2 overexpressing tumor cells.
Deucravacitinib: Sold under the brand name DUVACIDX. Deuterated colecitinib is a targeted therapy. Targeted therapy is the result of years of research aimed at understanding the differences between cancer cells and normal cells. Targeted therapy attacks cancer cells while minimizing damage to normal cells and reducing side effects.
Upadacitinib: Sold under the brand name UPADX. Upatinib is a new type of oral phosphodiesterase 4 inhibitor, which belongs to a kind of JAK inhibitor. It can reduce the inflammatory response and relieve the symptoms of inflammation-related diseases by inhibiting the activity of phosphodiesterase 4.
About Big Bear Pharma
Big Bear Pharma is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for cancer. The company has a diverse pipeline of anti-cancer targeted drugs that address various molecular pathways and mechanisms of action. Big Bear Pharma aims to improve the lives of patients with cancer by providing them with more options, better outcomes and lower costs.
Forward-Looking Statements
To the extent applicable laws and regulations, expressions such as "plan," "target," "expect," "forecast," and similar expressions appearing in this press release are forward-looking statements. The forward-looking statements set forth herein involve a number of risks and uncertainties that may differ materially from actual results. Important factors leading to such differences include, but are not limited to, changes in regulations and/or economic conditions, uncertainty in clinical research results, exposure to various market risks, and other factors beyond the control of the company.